

# Does Applying More Oxygen Cure Lower Extremity Sores?

Gepubliceerd: 09-04-2013 Laatst bijgewerkt: 19-03-2025

The hypothesis is that HBOT will have additional beneficial effect in terms of wound healing and/or limb salvage over conventional (surgical or non-surgical) care for diabetic patients with leg ischaemia, with acceptable costs.

|                             |                          |
|-----------------------------|--------------------------|
| <b>Ethische beoordeling</b> | Positief advies          |
| <b>Status</b>               | Werving nog niet gestart |
| <b>Type aandoening</b>      | -                        |
| <b>Onderzoekstype</b>       | Interventie onderzoek    |

## Samenvatting

### ID

NL-OMON28958

### Bron

NTR

### Verkorte titel

DAMOCLES

### Aandoening

Diabetic ischemic ulcers; leg ulcer; ischaemia; peripheral vascular disease; Diabetische ulcera; ischemie; perifeer vaatlijden

### Ondersteuning

**Primaire sponsor:** AMC, Amsterdam

**Overige ondersteuning:** ZonMW

### Onderzoeksproduct en/of interventie

### Uitkomstmaten

#### Primaire uitkomstmaten

Wound healing and limb salvage.

# Toelichting onderzoek

## Achtergrond van het onderzoek

Rationale:

Chronic leg ulcers in diabetic patients pose a major health problem. Conventional treatment is complex and costly. Current evidence on the (cost-)effectiveness of hyperbaric oxygen therapy (HBOT) as an adjunct to standard wound care is equivocal because studies have been heterogenous and have included small numbers of patients. As a consequence, cost-effectiveness is still unclear.

Objectives:

The primary objective is to assess whether the effectiveness of HBOT as an adjunct to standard wound care in preventing amputations and improving wound healing in ischemic diabetic ulcers justifies its costs.

Secondary objectives are to assess the quality of life and the need for vascular interventions following both treatments.

Study design:

Multicenter randomized controlled trial.

Study population:

275 diabetic patients with ischemic leg ulcers.

Intervention:

Patients will be randomly assigned to HBOT plus usual wound care or usual wound care only. HBOT will comprise 40 sessions, 90 minutes each, over an eight week period.

Main endpoints:

Primary endpoints are freedom of major (above ankle) amputations after 12 months, and occurrence of and time to complete wound healing.  
Secondary endpoints are pain scores, freedom of minor amputations after.

## **Doel van het onderzoek**

The hypothesis is that HBOT will have additional beneficial effect in terms of wound healing and/or limb salvage over conventional (surgical or non-surgical) care for diabetic patients with leg ischaemia, with acceptable costs.

## **Onderzoeksopzet**

Patients in both groups will be monitored for 12 months after inclusion. Throughout the 8 week treatment phase, all patients collect data about pain scores and wound healing. The questionnaires (costs, ALDS, SF-36, VASQUOL and EQ-5D) will be send to the patients home address, accompanied by a prepaid return envelope.

Subsequently follow-up is performed by the vascular surgeon after 8 weeks, 3 months, 6 months, 12 months and after any vascular intervention. During this visits at the outpatient clinic the surgeon will collect outcome measures as mentioned.

## **Onderzoeksproduct en/of interventie**

Patients are placed in an airtight cabin and receive 100% 2.5 ATA. A complete course of HBOT treatments involves 40 sessions, once daily, for 90 minutes.  
The control group will receive wound care as usual.

## **Contactpersonen**

### **Publiek**

Academic Medical Center (AMC), Department of Clinical Epidemiology and Biostatistics,  
P.O. Box 22660  
D.T. Ubbink  
Meibergdreef 9  
Amsterdam 1100 DD  
The Netherlands  
+31 (0)20 5666892

### **Wetenschappelijk**

Academic Medical Center (AMC), Department of Clinical Epidemiology and Biostatistics,  
P.O. Box 22660  
D.T. Ubbink

Meibergdreef 9  
Amsterdam 1100 DD  
The Netherlands  
+31 (0)20 5666892

## Deelname eisen

### Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)

1. Type I or II diabetes
2. Wagner 2, 3 or 4 lower extremity ulcer(s), present for at least 4 weeks. In case more than one ulcer is present, the largest will be observed as target ulcer.
3. Leg ischemia, characterized by a highest ankle systolic blood pressure < 70 mmHg, or a toe systolic pressure < 50 mmHg or a TcpO<sub>2</sub> < 40 mmHg
4. Complete assessment of peripheral arterial lesions from the aorta to the pedal arteries with duplex ultrasonography, magnetic resonance angiography, computed tomography angiography and/or intra-arterial digital subtraction angiography of the ipsilateral leg
5. Age ≥ 18 years
6. Written informed consent

### Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)

1. Previous major amputation of the leg with the index ulcer
2. Chronic Obstructive Pulmonary Disease (COPD) GOLD IV
3. Current treatment with chemotherapy, immunosuppressive drugs or systemic corticosteroids (daily 10mg or more), as this interferes with normal wound healing
4. End stage renal disease requiring dialysis
5. Metastatized malignancy
6. Left ventricular failure with ejection fraction (EF) <20% or external pacemaker

7. Pregnancy

8. Insufficient proficiency of Dutch language, or inability to complete the Dutch questionnaires or not compos mentis.

## Onderzoeksopzet

### Opzet

|                  |                       |
|------------------|-----------------------|
| Type:            | Interventie onderzoek |
| Onderzoeksmodel: | Parallel              |
| Toewijzing:      | Gerandomiseerd        |
| Blinding:        | Enkelblind            |
| Controle:        | Geneesmiddel          |

### Deelname

|                         |                          |
|-------------------------|--------------------------|
| Nederland               |                          |
| Status:                 | Werving nog niet gestart |
| (Verwachte) startdatum: | 01-07-2013               |
| Aantal proefpersonen:   | 275                      |
| Type:                   | Verwachte startdatum     |

## Ethische beoordeling

|                 |                  |
|-----------------|------------------|
| Positief advies |                  |
| Datum:          | 09-04-2013       |
| Soort:          | Eerste indiening |

## Registraties

### Opgevolgd door onderstaande (mogelijk meer actuele) registratie

ID: 41563

Bron: ToetsingOnline

Titel:

## **Andere (mogelijk minder actuele) registraties in dit register**

Geen registraties gevonden.

## **In overige registers**

| <b>Register</b> | <b>ID</b>                           |
|-----------------|-------------------------------------|
| NTR-new         | NL3779                              |
| NTR-old         | NTR3944                             |
| CCMO            | NL44429.018.13                      |
| ISRCTN          | ISRCTN wordt niet meer aangevraagd. |
| OMON            | NL-OMON41563                        |

## **Resultaten**

### **Samenvatting resultaten**

N/A